Champions Oncology (CSBR) EV to EBITDA (2011 - 2026)

Champions Oncology has reported EV to EBITDA for 16 years, with the latest figure at 158.8 in Q2 2026.

• On a quarterly basis, EV to EBITDA fell 259.23% year-over-year to 158.8 in Q2 2026; TTM through Apr 2026 was 72.71, a 473.15% decrease from a year earlier, with the FY2026 full-year figure at 72.71, down 473.15% from the prior year.
• EV to EBITDA was 158.8 for Q2 2026 at Champions Oncology, up from 342.32 in the prior quarter.
• The five-year high for EV to EBITDA was 11895.86 in Q4 2022, with the low at 383.82 in Q3 2022.
• Average EV to EBITDA over 5 years is 604.57, with a median of 30.66 recorded in 2024.
• The sharpest annual moves came in 2022 and 2026: EV to EBITDA surged 2362.36% in 2022, then tumbled 1144.69% in 2026.
• Over 5 years, EV to EBITDA stood at 11895.86 in 2022, then plunged by 100.3% to 35.15 in 2023, then surged by 297.5% to 69.41 in 2024, then jumped by 573.84% to 467.72 in 2025, then tumbled by 133.95% to 158.8 in 2026.
• The last three EV to EBITDA figures came in at 158.8 (Q2 2026), 342.32 (Q1 2026), and 467.72 (Q4 2025), per Business Quant data.